Category Archives: IP

PhRMA Dismayed by Global IPR Report

Also posted in Global, Guest Blog, Regulatory | Tagged , , , | Leave a comment

Drug Pipelines in Canada: Is There a Buyer for Future Innovation?

Last week, Canada’s National Prescription Drug Utilization Information System (NPDUIS), a federal-provincial fact-finding panel that works closely with the Patented Medicines Prices Review Board (PMPRB), issued its fourth New Drug Pipeline Monitor (NDPM) looking at drugs currently under development that may have an impact on future drug expenditures. The report is another example of how […]
Also posted in Global, healthcare, Market Access, Orphan Drugs, pricing, R&D, Regulatory | Tagged , , , , , | Leave a comment

Does India's Glivec Decision Make April Fools of Us All?

By Helen Disney, Pugatch Consilium. On April 1, India’s Supreme Court denied an appeal challenging the rejection of a patent for Novartis’s cancer drug, Glivec. The drug is a life-saving medicine for certain forms of cancer, patented in nearly 40 other countries — including many which are not noted for the strength of their intellectual […]
Also posted in Global, Guest Blog, Legal, Op-Ed | Tagged , , , | 2 Comments

The Patent Black Label: Six Side-Effects of India's Novartis Glivec Ruling

Monday’s decision by India’s Supreme Court to deny a patent for the top-selling oncologic drug Glivec took nearly a decade of litigation to resolve – but the implications in and beyond India are both immediate and lasting.  Here’s a list of six that Pharm Exec thinks are most important:
Also posted in Emerging Markets, Global, Legal, Manufacturing, Market Access, pricing, Strategy | Tagged , , , , , , , , | 6 Comments

The FTC's Beef with Pay For Delay: What's the Fuss?

Yesterday, the Supreme Court heard arguments on the matter of pay-for-delay settlements between patent holders and generic firms. The Federal Trade Commission (FTC) hopes to overturn the 11th federal circuit’s ruling that such settlements are not anti-competitive on the grounds that these settlements amount to a restraint of trade under the commerce clause of the […]
Also posted in Legal, Market Access, Regulatory | Tagged , , , , | 1 Comment
  • Categories

  • Meta